Estrella Immunopharma (ESLA) vs SeaStar Medical (ICU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SeaStar Medical (ICU) has outperformed Estrella Immunopharma (ESLA) over the past year, losing 47.0% versus a loss of 67.9%. Over five years, ESLA leads with a -95.8% price change compared with -99.9% for ICU. SeaStar Medical is the larger company by market cap ($18.4 million vs $18.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESLA | ICU |
|---|---|---|
| Share price | $0.4175 | $3.49 |
| Market cap | $18.16M | $18.36M |
| 1-day change | -0.43% | -6.18% |
| YTD return | -73.24% | +45.42% |
| 1-year return | -67.88% | -47.04% |
| 5-year return | -95.77% | -99.86% |
| EPS (TTM) | $-0.25 | $-2.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.15 | $7.35 |
| 52-week low | $0.361 | $2.07 |
| Distance from 52-week high | -86.75% | -52.52% |
| Analyst consensus | none | none |
| Avg. price target upside | +2774.25% | +186.53% |
| Average volume | 38.61K | 99.80K |
| Shares outstanding | 43.50M | 5.26M |
| Employees | — | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICU has outperformed ESLA by 20.8 percentage points over the past year.
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Healthcare · Biotechnology
About SeaStar Medical
ICU stock →SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
Healthcare · Biotechnology · 18 employees
ESLA vs ICU FAQ
Which is bigger, Estrella Immunopharma or SeaStar Medical?
SeaStar Medical (ICU) is larger, with a market capitalization of $18.36M compared with $18.16M for Estrella Immunopharma (ESLA).
Which stock has performed better over the past year, ESLA or ICU?
ICU returned -47.04% over the past 12 months, compared with -67.88% for ESLA (price return, excluding dividends). Past performance does not predict future results.
Are Estrella Immunopharma and SeaStar Medical in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.